A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr

Leukemia Research
A RazaH Preisler

Abstract

Ten patients with acute nonlymphocytic leukemia (ANLL) received bromodeoxyuridine (BrdU) at 100 mg/M2 intravenously over 1 h. BrdU is incorporated into the DNA by S-phase cells and was detected by using a monoclonal anti-BrdU antibody in the bone marrow aspirate (BM) and biopsy specimens obtained at the end of the infusion. Additionally, BM was incubated in vitro with tritiated thymidine (3HTdr) and processed by our previously described double-label method. This allowed us to measure the duration of S-phase (Ts) and total cell cycle time (Tc) of myeloblasts. Data revealed a higher number of S-phase cells from biopsies (21%) than BM (5%). The Ts ranged from 9 to 35 h and Tc ranged between 36 and 152 h in different patients. Using this method, data are available within 48 h and if shown to be clinically relevant, may be useful for prospective planning of therapy in individual patients.

References

Jan 1, 1978·Medical and Pediatric Oncology·H D Preisler
Dec 11, 1978·Biochimica Et Biophysica Acta·B T Hill
Apr 1, 1985·Cell Biochemistry and Function·C SpiridonidisH D Preisler
Jan 1, 1987·American Journal of Hematology·A RazaH D Preisler
Jan 1, 1985·Annals of the New York Academy of Sciences·P C Vincent
Jul 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·D V Santi, C S McHenry
Apr 12, 1984·The New England Journal of Medicine·A RazaR Bankert
Aug 1, 1967·The Journal of Clinical Investigation·E F SaundersA M Mauer

❮ Previous
Next ❯

Citations

Jan 8, 1999·Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie·J BoutonnatX Ronot
Jan 1, 1991·Acta Oncologica·A LaasonenL R Holsti
Jan 1, 1992·Medical Oncology and Tumor Pharmacotherapy·A M WenthzelP Reizenstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.